JPRN-UMIN000020177已完成未知
ong-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization - Long-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularization
Ophthalmology of Tokyo Medical and Dental University0 个研究点目标入组 51 人开始时间: 2015年12月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) a history of other treatments for myopic CNV (PDT, other anti-VEGF reagents than ranibizumab) 2) a history of vitreoretinal surgery 3) a presence of other ocular complications which could affect the vision (dense cataract, foveal retinal detachment, macular holes, etc.
研究者
相似试验
招募中
2 期
Comparative study of the effect of intravitreal injection of bevacizumab versus simultaneous intravitreal injection of bevacizumab and triamcinolone acetonideRetinal vascular occlusions.Retinal vascular occlusionsIRCT20130812014333N185Kermanshah University of Medical Sciences58
进行中（未招募）
1 期
ongterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.Choroidal neovascularisation and chronic macular edemaMedDRA version: 20.0Level: LLTClassification code 10054467Term: Macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 21.1Level: PTClassification code 10060823Term: Choroidal neovascularisationSystem Organ Class: 10015919 - Eye disordersEUCTR2013-005056-15-BEZ Gent800
招募中
不适用
The changes in visual function after intravitreal bevacizmab for ocular neovascular diseasesOcular neovascular diseasesJPRN-UMIN000021074Ophthalmology, Kagoshima university50
已完成
不适用
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal MembranesAge Related Macular DegenerationEpiretinal MembraneNCT01846351New England Retina Associates16
招募中
4 期
observational comparative study: Intravitreal treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with a bispecific antibody Vabysmo® (faricimab) vs. a classical anti-VEGF inhibitor Eylea® (aflibercept) in a treat-and-extend-regimen (FATE).H35.30H36.0Diabetic retinopathyDRKS00031548Augenklinik der Medizinischen Hochschule Hannover136